25Th Meeting of the Technical Advisory Group on Immunization and Vaccine Preventable Diseases, 26-29 July
Total Page:16
File Type:pdf, Size:1020Kb
RS/2016/GE/50(PHL) English only WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC MEETING REPORT 25th Meeting of the Technical Advisory Group on Immunization and Vaccine- Preventable Diseases Convened by: WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC Manila, Philippines 26−29 July 2016 Not for sale Printed and distributed by: World Health Organization Regional Office for the Western Pacific Manila, Philippines September 2016 NOTE The views expressed in this report are those of the participants of the 25th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region and do not necessarily reflect the policies of the conveners. The Expanded Programme on Immunization of the WHO Regional Office for the Western Pacific would like to thank Japan Voluntary Contribution, Gavi, the Vaccine Alliance and U.S. Centers for Disease Control and Prevention for providing financial support for the meeting, including the production of this report. This report has been prepared by the World Health Organization Regional Office for the Western Pacific for Member States in the Region and for those who participated in the 25th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region in Manila, Philippines, from 26 to 29 July 2016. 2 1. CONTENTS 1. CONTENTS ................................................................................................................................................... 3 2. SUMMARY ................................................................................................................................................... 7 3. INTRODUCTION .......................................................................................................................................... 8 3.1. Meeting organization ............................................................................................................................ 8 3.2. Meeting objectives ................................................................................................................................ 8 4. PROCEEDINGS ............................................................................................................................................. 8 4.1. OPENING SESSION ............................................................................................................................ 8 4.2. Update on Implementation of Global Vaccine Action Plan (GVAP) .................................................... 9 4.3. Update from Strategic Advisory Group of Experts ............................................................................... 9 4.4. Sustaining polio-free status and implementation of polio endgame strategies .................................... 10 4.4.1. Global update ...................................................................................................................................... 10 4.4.2. Regional update ................................................................................................................................... 10 4.4.3. Polio laboratory network and environmental surveillance update ...................................................... 11 4.4.4. Global Polio Eradication Initiative outbreak response ........................................................................ 11 4.4.5. Country presentation – outbreak of circulating vaccine-derived poliovirus ........................................ 11 4.4.6. Trivalent oral polio vaccine bivalent oral polio vaccine switch and inactivated polio vaccine supply12 4.4.7. Country presentations.......................................................................................................................... 12 4.4.8. Laboratory containment ...................................................................................................................... 13 4.5. Hepatitis B accelerated control ........................................................................................................... 13 4.5.1. Global/regional update ........................................................................................................................ 13 4.6. Japanese encephalitis (JE) accelerated control .................................................................................... 14 4.6.1. Global/regional update ........................................................................................................................ 14 4.6.2. Western Pacific Region JE laboratory network................................................................................... 14 4.6.3. JE outbreak in the Philippines ............................................................................................................. 14 4.6.4. Ethics Review Committee update (targets, strategies and timeliness) ................................................ 15 4.7. Measles and rubella elimination .......................................................................................................... 15 4.7.1. Global update ...................................................................................................................................... 15 3 4.7.2. Regional overview and draft Regional Strategy .................................................................................. 15 4.7.3. Country presentations.......................................................................................................................... 16 4.7.4. Proposed strategy for immunization ................................................................................................... 18 4.7.5. Country presentation – epidemiologic surveillance ............................................................................ 19 4.7.6. Proposed strategy for epidemiologic surveillance ............................................................................... 19 4.7.7. Country presentation – laboratory support .......................................................................................... 19 4.7.8. Proposed strategy for laboratory support ............................................................................................ 20 4.7.9. Country presentation – outbreak preparedness and response .............................................................. 20 4.7.10. Proposed strategy for outbreak preparedness and response ............................................................ 22 4.7.11. Regional Verification Commission ................................................................................................. 22 4.7.12. National Verification Commission ................................................................................................. 22 4.7.13. Proposed strategy for other strategic areas ..................................................................................... 22 4.8. Maternal and Neonatal Tetanus Elimination (MNTE) ........................................................................ 23 4.8.1. Regional Update .................................................................................................................................. 23 4.9. Strengthening immunization systems (including strengthening routine immunization programme) .. 23 4.9.1. Global perspective on strengthening routine immunization programme: Global Routine Immunization Strategies Practices (GRISP) ..................................................................................................... 23 4.9.2. Closing gaps: addressing inequity in the regional context .................................................................. 23 4.9.3. Achieving high and equitable immunization in urban settings ........................................................... 24 4.9.4. Life course approach; school-based immunization – New Zealand .................................................... 25 4.9.5. Vaccine security; Implementation plan for Effective Vaccine Management (EVM) in Papua New Guinea 25 4.9.6. Diphtheria in the Philippines ............................................................................................................... 26 4.9.7. Strengthening evidence-based decision making .................................................................................. 26 4.9.8. Lessons learnt (functional National Immunization Technical Advisory Groups [NITAG]) ............... 27 4.9.9. Data quality in Western Pacific Region countries: overview, challenges, opportunities .................... 27 4.9.10. Data quality assessment and data improvement plan ...................................................................... 27 4.9.11. Lessons to learn from implementing Electronic Immunization Registry ........................................ 28 4.9.12. Regional vaccine regulatory update ................................................................................................ 28 4.9.13. Global and regional vaccine safety update ..................................................................................... 28 4.10. Introduction of New and Underutilized Vaccine (NUVI) ................................................................... 29 4 4.10.1. Global/Regional NUVI update ....................................................................................................... 29 4.10.2. Surveillance networks ..................................................................................................................... 29